Comparative effects of dexmedetomidine, propofol, sevoflurane, and S-ketamine on regional cerebral glucose metabolism in humans [Elektronisk resurs] a positron emission tomography study
-
Laaksonen, L. (författare)
-
Kallioinen, M. (författare)
-
Löngsjö, J. (författare)
-
Laitio, T. (författare)
-
Scheinin, A. (författare)
-
Scheinin, J. (författare)
-
Kaisti, K. (författare)
-
Maksimow, A. (författare)
-
Kallionpää, R. E. (författare)
-
Rajala, V. (författare)
-
Johansson, Jarkko (författare)
-
Kantonen, O. (författare)
-
Nyman, M. (författare)
-
Sirén, S. (författare)
-
Valli, K. (författare)
-
Revonsuo, A. (författare)
-
Solin, O. (författare)
-
Vahlberg, T. (författare)
-
Alkire, M. (författare)
-
Scheinin, H. (författare)
-
Umeå universitet Medicinska fakulteten (utgivare)
- Publicerad: Elsevier, 2018
- Engelska.
-
Ingår i: British Journal of Anaesthesia. - 0007-0912. ; 121:1, 281-290
-
Läs hela texten
-
Läs hela texten
-
Läs hela texten
Sammanfattning
Ämnesord
Stäng
- Introduction: The highly selective α 2 -agonist dexmedetomidine has become a popular sedative for neurointensive care patients. However, earlier studies have raised concern that dexmedetomidine might reduce cerebral blood flow without a concomitant decrease in metabolism. Here, we compared the effects of dexmedetomidine on the regional cerebral metabolic rate of glucose (CMR glu ) with three commonly used anaesthetic drugs at equi-sedative doses. Methods: One hundred and sixty healthy male subjects were randomised to EC 50 for verbal command of dexmedetomidine (1.5 ng ml -1 ; n =40), propofol (1.7 μg ml -1 ; n =40), sevoflurane (0.9% end-tidal; n =40) or S-ketamine (0.75 μg ml −1 ; n =20) or placebo ( n =20). Anaesthetics were administered using target-controlled infusion or vapouriser with end-tidal monitoring. 18 F-labelled fluorodeoxyglucose was administered 20 min after commencement of anaesthetic administration, and high-resolution positron emission tomography with arterial blood activity samples was used to quantify absolute CMR glu for whole brain and 15 brain regions. Results: At the time of [F 18 ]fluorodeoxyglucose injection, 55% of dexmedetomidine, 45% of propofol, 85% of sevoflurane, 45% of S-ketamine, and 0% of placebo subjects were unresponsive. Whole brain CMR glu was 63%, 71%, 71%, and 96% of placebo in the dexmedetomidine, propofol, sevoflurane, and S-ketamine groups, respectively ( P <0.001 between the groups). The lowest CMR glu was observed in nearly all brain regions with dexmedetomidine ( P <0.05 compared with all other groups). With S-ketamine, CMR glu did not differ from placebo. Conclusions: At equi-sedative doses in humans, potency in reducing CMR glu was dexmedetomidine>propofol>ketamine=placebo. These findings alleviate concerns for dexmedetomidine-induced vasoconstriction and cerebral ischaemia.
Ämnesord
- Medical and Health Sciences (hsv)
- Clinical Medicine (hsv)
- Anesthesiology and Intensive Care (hsv)
- Medicin och hälsovetenskap (hsv)
- Klinisk medicin (hsv)
- Anestesi och intensivvård (hsv)
- Medical and Health Sciences (hsv)
- Other Medical Sciences (hsv)
- Other Medical Sciences not elsewhere specified (hsv)
- Medicin och hälsovetenskap (hsv)
- Annan medicin och hälsovetenskap (hsv)
- Övrig annan medicin och hälsovetenskap (hsv)
Indexterm och SAB-rubrik
- cerebral blood flow
- cerebral metabolism
- positron emission tomography
- sedation
- target-controlled infusion
Inställningar
Hjälp
Beståndsinformation saknas